Gideon Lewis, MD
Adult Medicine · Winter Park, FLNPI 1508845116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $421 and has fallen 53.2% since, to $197 in 2025.
Across 83 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$288
- AbbVie$189
- Boehringer Ingelheim$179
- GSK$144
- Novo Nordisk$118
- Lilly USA, LLC$91
- plus $747 from 16 others
What the payments were for
- Food & beverage$1,757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $288 |
| AbbVie | 6 | $189 |
| Boehringer Ingelheim | 8 | $179 |
| GSK | 8 | $144 |
| Novo Nordisk | 8 | $118 |
| Lilly USA, LLC | 4 | $91 |
| Sunovion Pharmaceuticals Inc. | 4 | $91 |
| Abbott | 4 | $82 |
| Amgen | 4 | $75 |
| Zimmer Biomet | 1 | $67 |
| Stryker | 2 | $66 |
| Smith+Nephew | 2 | $59 |
| Pfizer | 3 | $59 |
| Pacira Therapeutics, Inc. | 2 | $54 |
| Misonix Inc | 2 | $46 |
| Merck | 2 | $38 |
| Reel Surgical, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$119
How this compares
$1,757 in reported general payments places this provider in the 80th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $57,071 |
| JardianceEmpagliflozin | 37 | $49,964 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $47,352 |
| FarxigaDapagliflozin Propanediol | 42 | $46,593 |
| EliquisApixaban | 36 | $35,690 |
| XareltoRivaroxaban | 20 | $14,744 |
| JanuviaSitagliptin Phosphate | 18 | $14,367 |
| TradjentaLinagliptin | 14 | $13,006 |
| MyrbetriqMirabegron | 11 | $11,944 |
| MounjaroTirzepatide | 11 | $11,226 |
| Bydureon BciseExenatide Microspheres | 12 | $9,970 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,335 |
| SynthroidLevothyroxine Sodium | 46 | $3,112 |
| Losartan Potassium | 302 | $2,803 |
| Levothyroxine Sodium | 285 | $2,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $179 | $62,97051 claims |
| Novo NordiskOzempic | $118 | $57,07139 claims |
| GSKTrelegy Ellipta | $144 | $47,35250 claims |
| AstraZenecaFarxiga | $288 | $46,59342 claims |
| PfizerEliquis | $59 | $35,69036 claims |
| Johnson & JohnsonXarelto | $17 | $14,74420 claims |
| MerckJanuvia | $38 | $14,36718 claims |
| Lilly USA, LLCMounjaro | $91 | $11,22611 claims |
| AbbVieSynthroid | $189 | $3,11246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Winter Park
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
- Hernando ChongMiami$9K
- Neri FranzonFt Lauderdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.